PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

MLA

Anne Vincent-Salomon, et al. “PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.” Cancers, vol. 13, no. 4, Feb. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....21bf56785125ba0273a1da570bf00a86&authtype=sso&custid=ns315887.

APA

Anne Vincent-Salomon, Fabien Reyal, Beatriz Grandal, Elsy El-Alam, Marick Laé, Anne-Sophie Hamy, Eric Daoud, Lauren Darrigues, Elise Dumas, Guillaume Bataillon, Manon Mangiardi-Veltin, Enora Laas, Laure-Sophie Talagrand, Didier Meseure, & Jean-Yves Pierga. (2021). PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers, 13(4).

Chicago

Anne Vincent-Salomon, Fabien Reyal, Beatriz Grandal, Elsy El-Alam, Marick Laé, Anne-Sophie Hamy, Eric Daoud, et al. 2021. “PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.” Cancers 13 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....21bf56785125ba0273a1da570bf00a86&authtype=sso&custid=ns315887.